A citation-based method for searching scientific literature

Margarida M Moura, Branca M Cavaco, Valeriano Leite. Endocr Relat Cancer 2015
Times Cited: 58







List of co-cited articles
467 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Samuel A Wells, Sylvia L Asa, Henning Dralle, Rossella Elisei, Douglas B Evans, Robert F Gagel, Nancy Lee, Andreas Machens, Jeffrey F Moley, Furio Pacini,[...]. Thyroid 2015
960
56

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
865
44

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
673
43

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Rossella Elisei, Barbara Cosci, Cristina Romei, Valeria Bottici, Giulia Renzini, Eleonora Molinaro, Laura Agate, Agnese Vivaldi, Pinuccia Faviana, Fulvio Basolo,[...]. J Clin Endocrinol Metab 2008
324
39

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Margarida M Moura, Branca M Cavaco, António E Pinto, Valeriano Leite. J Clin Endocrinol Metab 2011
153
31

Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.
Nishant Agrawal, Yuchen Jiao, Mark Sausen, Rebecca Leary, Chetan Bettegowda, Nicholas J Roberts, Sheetal Bhan, Allen S Ho, Zubair Khan, Justin Bishop,[...]. J Clin Endocrinol Metab 2013
144
29

High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.
Michele Simbolo, Caterina Mian, Susi Barollo, Matteo Fassan, Andrea Mafficini, Diogo Neves, Maria Scardoni, Gianmaria Pennelli, Massimo Rugge, Maria Rosa Pelizzo,[...]. Virchows Arch 2014
57
26

Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Raffaele Ciampi, Caterina Mian, Laura Fugazzola, Barbara Cosci, Cristina Romei, Susi Barollo, Valentina Cirello, Valeria Bottici, Giulia Marconcini, Pelizzo Maria Rosa,[...]. Thyroid 2013
109
25

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Martin Schlumberger, Barbara Jarzab, Maria E Cabanillas, Bruce Robinson, Furio Pacini, Douglas W Ball, Judith McCaffrey, Kate Newbold, Roger Allison, Renato G Martins,[...]. Clin Cancer Res 2016
137
22


Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
Samuel A Wells, Furio Pacini, Bruce G Robinson, Massimo Santoro. J Clin Endocrinol Metab 2013
183
22

Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
Jun Ho Ji, Young Lyun Oh, Mineui Hong, Jae Won Yun, Hyun-Woo Lee, DeokGeun Kim, Yongick Ji, Duk-Hwan Kim, Woong-Yang Park, Hyun-Tae Shin,[...]. PLoS Genet 2015
76
22

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.
M M Moura, B M Cavaco, A E Pinto, R Domingues, J R Santos, M O Cid, M J Bugalho, V Leite. Br J Cancer 2009
102
20

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Cristina Romei, Raffaele Ciampi, Rossella Elisei. Nat Rev Endocrinol 2016
168
18

Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing.
Raffaele Ciampi, Cristina Romei, Teresa Ramone, Alessandro Prete, Alessia Tacito, Virginia Cappagli, Valeria Bottici, David Viola, Liborio Torregrossa, Clara Ugolini,[...]. iScience 2019
55
20

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
974
17

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
858
17


RET fusion as a novel driver of medullary thyroid carcinoma.
Elizabeth G Grubbs, Patrick Kwok-Shing Ng, Jacquelin Bui, Naifa L Busaidy, Ken Chen, Jeffrey E Lee, Xinyan Lu, Hengyu Lu, Funda Meric-Bernstam, Gordon B Mills,[...]. J Clin Endocrinol Metab 2015
49
20

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
L M Mulligan, J B Kwok, C S Healey, M J Elsdon, C Eng, E Gardner, D R Love, S E Mole, J K Moore, L Papi. Nature 1993
17

Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
A Boichard, L Croux, A Al Ghuzlan, S Broutin, C Dupuy, S Leboulleux, M Schlumberger, J M Bidart, L Lacroix. J Clin Endocrinol Metab 2012
91
17

RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC).
C Romei, B Cosci, G Renzini, V Bottici, E Molinaro, L Agate, P Passannanti, D Viola, A Biagini, F Basolo,[...]. Clin Endocrinol (Oxf) 2011
70
15

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Ezra E W Cohen, Lee S Rosen, Everett E Vokes, Merrill S Kies, Arlene A Forastiere, Francis P Worden, Madeleine A Kane, Eric Sherman, Sinil Kim, Paul Bycott,[...]. J Clin Oncol 2008
463
13

The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
C Eng, D Clayton, I Schuffenecker, G Lenoir, G Cote, R F Gagel, H K van Amstel, C J Lips, I Nishisho, S I Takai,[...]. JAMA 1996
776
13

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
13

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Francesca Carlomagno, Donata Vitagliano, Teresa Guida, Fortunato Ciardiello, Giampaolo Tortora, Giancarlo Vecchio, Anderson J Ryan, Gabriella Fontanini, Alfredo Fusco, Massimo Santoro. Cancer Res 2002
481
12

Medullary thyroid cancer: management guidelines of the American Thyroid Association.
Richard T Kloos, Charis Eng, Douglas B Evans, Gary L Francis, Robert F Gagel, Hossein Gharib, Jeffrey F Moley, Furio Pacini, Matthew D Ringel, Martin Schlumberger,[...]. Thyroid 2009
815
12


Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer.
Cristina Romei, Clara Ugolini, Barbara Cosci, Liborio Torregrossa, Agnese Vivaldi, Raffaele Ciampi, Alessia Tacito, Fulvio Basolo, Gabriele Materazzi, Paolo Miccoli,[...]. Thyroid 2012
39
17

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Samuel A Wells, Jessica E Gosnell, Robert F Gagel, Jeffrey Moley, David Pfister, Julie A Sosa, Michael Skinner, Annetta Krebs, James Vasselli, Martin Schlumberger. J Clin Oncol 2010
351
12

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Elaine T Lam, Matthew D Ringel, Richard T Kloos, Thomas W Prior, Michael V Knopp, Jiachao Liang, Steffen Sammet, Nathan C Hall, Paul E Wakely, Vasyl V Vasko,[...]. J Clin Oncol 2010
276
12

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.
Francesca Carlomagno, Teresa Guida, Suresh Anaganti, Giancarlo Vecchio, Alfredo Fusco, Anderson J Ryan, Marc Billaud, Massimo Santoro. Oncogene 2004
184
12

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
S Dvorakova, E Vaclavikova, V Sykorova, J Vcelak, Z Novak, J Duskova, A Ryska, J Laco, J Cap, D Kodetova,[...]. Mol Cell Endocrinol 2008
73
12

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Steven I Sherman, Douglas O Clary, Rossella Elisei, Martin J Schlumberger, Ezra E W Cohen, Patrick Schöffski, Lori J Wirth, Milan Mangeshkar, Dana T Aftab, Marcia S Brose. Cancer 2016
57
12

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
192
12

Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid.
Mauro Papotti, Martina Olivero, Marco Volante, Francesco Negro, Maria Prat, Paolo M. Comoglio, Maria Flavia DiRenzo. Endocr Pathol 2000
62
10

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Laurie L Carr, David A Mankoff, Bernardo H Goulart, Keith D Eaton, Peter T Capell, Elizabeth M Kell, Julie E Bauman, Renato G Martins. Clin Cancer Res 2010
286
10

Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine.
E Modigliani, R Cohen, J M Campos, B Conte-Devolx, B Maes, A Boneu, M Schlumberger, J C Bigorgne, P Dumontier, L Leclerc,[...]. Clin Endocrinol (Oxf) 1998
356
10

Molecular pathology of hereditary and sporadic medullary thyroid carcinomas.
Rebecca D Chernock, Ian S Hagemann. Am J Clin Pathol 2015
18
33

Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
Caterina Mian, Gianmaria Pennelli, Susi Barollo, Elisabetta Cavedon, Davide Nacamulli, Federica Vianello, Isabella Negro, Giulia Pozza, Isabella Merante Boschin, Maria Rosa Pelizzo,[...]. Eur J Endocrinol 2011
64
10

Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers.
Julio C Ricarte-Filho, Sheng Li, Maria E R Garcia-Rendueles, Cristina Montero-Conde, Francesca Voza, Jeffrey A Knauf, Adriana Heguy, Agnes Viale, Tetyana Bogdanova, Geraldine A Thomas,[...]. J Clin Invest 2013
145
10

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.
D J Marsh, D L Learoyd, S D Andrew, L Krishnan, R Pojer, A L Richardson, L Delbridge, C Eng, B G Robinson. Clin Endocrinol (Oxf) 1996
156
10


Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
C Eng, D P Smith, L M Mulligan, M A Nagai, C S Healey, M A Ponder, E Gardner, G F Scheumann, C E Jackson, A Tunnacliffe. Hum Mol Genet 1994
440
10

RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation.
P Ballerini, S Struski, C Cresson, N Prade, S Toujani, C Deswarte, S Dobbelstein, A Petit, H Lapillonne, E-F Gautier,[...]. Leukemia 2012
66
10

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.
T C Schneider, D de Wit, T P Links, N P van Erp, J J M van der Hoeven, H Gelderblom, T van Wezel, R van Eijk, H Morreau, H J Guchelaar,[...]. Int J Endocrinol 2015
34
17

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
Keith C Bible, Vera J Suman, Julian R Molina, Robert C Smallridge, William J Maples, Michael E Menefee, Joseph Rubin, Nina Karlin, Kostandinos Sideras, John C Morris,[...]. J Clin Endocrinol Metab 2014
73
10

Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
David S Hong, Maria E Cabanillas, Jennifer Wheler, Aung Naing, Apostolia M Tsimberidou, Lei Ye, Naifa L Busaidy, Steven G Waguespack, Mike Hernandez, Adel K El Naggar,[...]. J Clin Endocrinol Metab 2011
78
10

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
560
10

Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Elizabeth G Grubbs, Michelle D Williams, Paul Scheet, Selina Vattathil, Nancy D Perrier, Jeffrey E Lee, Robert F Gagel, Tao Hai, Lei Feng, Maria E Cabanillas,[...]. Thyroid 2016
25
24


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.